Hepion pharmaceuticals updates on crv431's ability to decrease liver fibrosis

Hepion pharmaceuticals, inc. announced that it will present at the liver meeting 2019, hosted by the american association for the study of liver diseases (aasld), to be held in boston, ma from november 8-12, 2019. the poster presentation will address crv431's ability to decrease liver fibrosis in a carbon tetrachloride mouse model of liver injury and compare its activity to obeticholic acid, a leading, late clinical-phase drug candidate for nash. crv431 was found to concentrate in the liver, the intended site of action, which helps to explain its efficacious activity.
HEPA Ratings Summary
HEPA Quant Ranking